Brainomix, a member of the Scale Up 1st Cohort, is an acclaimed spin-out from the University of Oxford advancing stroke care through its AI-driven imaging biomarkers and software solutions. Their 360 Stroke platform stands out as the most comprehensive stroke imaging solution, widely utilized by healthcare systems globally to aid physicians in making informed treatment decisions. It offers a suite of tools that help detect blockages and bleeding in CT scans, evaluates blood flow, estimates the volume of damaged and at risk brain tissue, and tracks patients eligibility for clinical trials. 

Backed by Boehringer Ingelheim, Brainomix has successfully secured over $35 million in funding, concentrating on stroke care while seeking to lower healthcare costs and explore other imaging applications. In 2024, the company celebrated a significant achievement when NICE endorsed the Brainomix 360 Stroke platform, enhancing patient access to life-changing treatments. Brainomix is now looking to expand into new fields with similar unmet needs and opportunities to improve treatment processes around the world.

Brainomix in Three:

What problem is Brainomix solving?

Brainomix addresses the pressure that stroke cases place on healthcare systems by providing solutions that help physicians make informed decisions in stroke care.

What’s innovative about Brainomix?

The company leverages AI technology to create imaging biomarkers and software solutions specifically for improving stroke diagnosis and treatment, as well lung fibrosis.

Who can use Brainomix?

Brainomix's solutions are designed for healthcare professionals in the medical imaging space, particularly physicians involved in stroke care.

Brainomix has received approval for its groundbreaking work across multiple fronts, from investors to top-tier corporations and institutions, including Boehringer Ingelheim and the FDA.